Abstract
Synthetic glucocorticoids, such as dexamethasone and prednisolone, are commonly used in the treatment of patients with inflammatory conditions and autoimmune disorders. However, the multiple physiological effects that glucocorticoids exert can often result in short‐ and long‐term adverse drug reactions, including neuropsychiatric adverse events. Despite the widespread use of glucocorticoids, the prevalence of neuropsychiatric adverse events with these medications, while believed to be common, has not been rigorously quantified.